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Background: Genetic risk factors for sporadic pancreatic cancer are largely unknown but
actually under high exposure. Findings of correlations between the AB0 blood group
system (Chromosome 9q34,1—q34,2) and the risk of pancreatic cancer (PC) in patients
from Asia, America and south Europe have already been published. So far it is unclear,
whether this correlation between blood group an PC incidence can be found in German
patients as well.
Methods: One hundred and sixty-six patients who underwent a resection of PC were
evaluated in a period between 2000 and 2010. Blood group reference distribution for the
German population is given as: 0: 41%; A: 43%; B: 11%; AB: 5%; Rhesus positive: 85%;
Rhesus negative: 15%. Analyses were done using the non-parametric Chi2-test (p-value
two sided; SPSS 19.0).
Results: Median age was 62 (34–82) years. Gender: female 73/44%; male: 93/56%.
Observed blood group proportions: 0: 43 (25.9%)/A: 94 (56.6%)/B: 16 (9.6%)/AB: 13
(7.8%)/Rhesus positive: 131 (78.9%)/negative: 35 (21.1%). We detected a significant
difference to the German reference distribution of the AB0 system (Chi2 19.34, df 3,
p < 0.001). Rhesus factor has no impact on AB0-distribution (Chi2 4.13, df 3, p = 0.25),
but differs significantly from reference distribution—probably due to initial AB0-variation
(Chi2 4.82, df 1, p = 0.028). The odds ratio for blood group A is 2.01 and for blood group 0
is 0.5.
Conclusions: The incidence of PC in the German cohort is highly associated with the
AB0-system aswell. More patients with blood group A suffer from PC (p < 0.001) whereas
blood group 0 was less frequent in patients with PC (p < 0.001). Thus, our findings
support the results from other non-German surveys. The causal trigger points of this
carcinogenesis correlation are still not known.
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INTRODUCTION
Advanced pancreatic cancer holds one of the highest mortal-
ity rates of any cancer, with corresponding 5 year survival rate
of less than 5% (Adler et al., 2007; Pelzer, 2008). It remains
one of the leading causes of cancer-related deaths worldwide,
reflected by an incidence of 277,668 new cases and almost the
same mortality rate (266,029 cases) per year (Jemal et al., 2010).
Due to early disease symptoms being absent, only up to 20%
of patients can have their cancer resected with curative intent,
however, probably due to early lymphogenic spread or micro
metastasis, the 5-year overall survival rate of resected patients is
only 15–22% in spite of adjuvant treatment. An effective screen-
ing method or test for this devastating cancer is still missing.
Established risk factors include a family history of pancreatic can-
cer, a medical history of hereditary pancreatitis, diabetes type II
and cigarette smoking. Established research groups seeking for
predefined genome aberrations correlated to pancreatic cancer
(Amundadottir et al., 2009; He et al., 2013). In recent time
several studies investigating the possible correlation of the AB0
blood group system to pancreatic cancer (Yeo and Lowenfels,
2012) were published. Correlations were found in many pop-
ulations, exemplary in Turkish patients (Engin et al., 2012),
Korean patients (Woo et al., 2013), Japanese patients (Nakao
et al., 2011), Italian patients (Iodice et al., 2010), and North
American patients (Greer et al., 2010; Wolpin et al., 2010). But
there is no overall accordance in all populations. For instance in
Chinese patients publications showed inconsistent results with-
out detection of correlations on the one hand (Gong et al., 2012)
and proof of coherence on the other hand (Ben et al., 2011).
These assured correlations are not consistent over all malignan-
cies (Khalili et al., 2011). Currently no published survey data
of German patients or a central Europe cohort exists which
could help clarify the possible coherence. For further detection
of causality it is important to know whether these findings are
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valid for German patients as well, therefore we conducted this
investigation.
MATERIALS AND METHODS
Patients who underwent a resection of PC were evaluated in a
period between 2000 and 2010. All patients suffered from his-
tologically confirmed pancreatic cancer. Blood type assay from
166 patients (AB0 antigen and Rhesus antigen) were conducted.
As reference cohort, healthy blood donors from our department
of transfusion medicine were tested, whose blood types showed
the same distribution as the reference distribution of the German
population. Reference distribution was given as: blood group 0
41%; blood group A 43%; blood group B 11%; blood group AB
5%; Rhesus antigen positive 85% and Rhesus antigen negative
15%. In addition to descriptive analyses non-parametric Chi2-
tests (p-value two sided; SPSS 19.0) were used for comparisons.
RESULTS
The present, non-selected population of patients with pancre-
atic cancer reflects the general population with PC in Germany
as you can find in many trials. The median age was 62 (34–82)
years. The gender distribution favors male patients with a per-
centage of 56% male patients to 44% female patients (Table 1).
We observed blood group 0 in 43 (25.9%) patients, blood group
A in 94 (56.6%) patients, blood group B in 16 (9.6%) patients
and blood group AB in 13 (7.8%) patients. These observations
differ significantly from the reference distribution of the AB0 sys-
tem (Chi2 19.34, df 3, p < 0.001). The absolute differences to
the expected AB0-distribution were minus 25 patients for blood
group 0, plus 23 for blood group A, minus two patients for blood
group B and plus five patients for blood group AB. The odds
ratio for blood group A is 2.01 and for blood group 0 is 0.5. The
Chi2-tests for the single AB0-characters were as follow: for 0 (Chi2
15.64, df 1, p < 0.001), for A (Chi2 12.58, df 1, p < 0.001), for B
(Chi2 0.31, df 1, p = 0.58), and for AB (Chi2 2.80, df 1, p = 0.09)
(Figure 1, Table 2).
Furthermore we observed the positive rhesus antigen in 131
(78.9%) patients and the negative rhesus antigen in 35 (21.1%)
patients. The Rhesus factor has no significant impact on the
AB0-distribution (Chi2 4.13, df 3, p = 0.25) within the observed
cohort. As compared to the reference cohort, the distribution of
the Rhesus factor resulted in a significant difference (Chi2 4.82,
Table 1 | Patients’ characteristics.
Characteristic Patients
Included 166
Age: median [range] 62 [34–82] years
<60 years 63
60–70 years 69
>70 years 34
Gender
Female 73
Male 93
Biopsy proven adeno-carcinoma (pancreas) 166
df 1, p = 0.028). This observation is possibly boosted due to the
initial AB0-variation (Table 3).
DISCUSSION
In spite of recent advantages in the treatment modalities, like-
wise the FOLFIRINOX 1st-line regimen (Conroy et al., 2011),
the OFF 2nd-line treatment (Pelzer et al., 2011) or the latest data
from the gemcitabine/nab-paclitaxel 1st-line treatment, patients
suffering from pancreatic adenocarcinoma still have the poorest
survival outcome among cancer illnesses at all. Because of the
heavy difficulties in the treatment of advanced disease, increased
effort was dedicated to detect risk factors and causalities in the
carcinogenesis to diagnose patients at earliest point of disease.
Descriptions of observed correlations form the basis for further
investigations.
The characteristics of our observed patients were in accordance
with the appearance of the German clinician in terms of gender
and age (Adler et al., 2007). Thus, this cohort is representative for
patients with pancreatic carcinoma in Germany. Our findings are
not completely identical with the observations of other research
groups, but agree with risk lowering in patients with blood group
0. The Korean survey displayed an increased risk for the pop-
ulation with non-blood 0 character (Woo et al., 2013), Turkey
findings showed higher risk of patients with blood group A and
a lower risk of patients with blood group AB (Engin et al., 2012)
whereas Chinese patients were interestingly investigated without
blood group risk correlation (Gong et al., 2012). There are some
attempts to explain the observed correlations, mainly based on
the assumption of collocated signal cascade triggers. The chronic
pancreatitis is known to be a risk factor for carcinogenesis. A mis-
fit is that chronic pancreatitis was found to correlate with blood
group 0 (Greer et al., 2011) which on the other hand lower the risk
of pancreatic cancer. Another way of sourcing is the infection trig-
gered chronic inflammation. Helicobacter pylori infection is also
associated with the AB0 genotype mainly due to the AB0 antigen
expressions on gastrointestinal epithelium and therefore better
adhesion for the Helicobacter colonization. The positive associ-
ation between the AB0 expression and duodenal and gastric ulcer
as well as gastric cancers may base on effects of gastric and pan-
creatic secretory function disorders. This could have an additional
impact on the carcinogenicity of dietary- and smoking-related N-
nitrosamine exposures, and thus risk of pancreatic cancer (Risch,
2012).
Furthermore, venous thromboembolic events are also asso-
ciated with pancreatic cancer known as trousseaus syndrome,
first described in 1865. Is there a common base? Von Willebrand
factor (vWF) is one mediator for this cause. It has the blood
group antigens A and/or B on its surface and carries factor
VIII and protects it from degradation. Blood group A1 and
B educes a higher level of vWF and factor VIII. Thrombosis
may appear as an early observed symptom of the subsequent
diagnosis of pancreatic cancer. The activated coagulation was for-
merly described as an additional trigger associated with poor
prognosis and increased angiogenesis. There is supposedly a
combined cascade of carcinogenesis activation (Maisonneuve
et al., 2009). But, maybe as a result of earlier detection or
more effective therapy of thrombosis and thromboembolic
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FIGURE 1 | Network grafic—statistical distribution of blood group in Germany and for German patients with pancreatic cancer.
Table 2 | Calculations between single characters of group antigens.
Observed patients Expected patients
0 43 68.1 Chi2 19.34 df 3
p < 0.001
A 94 71.4
B 16 18.3
AB 13 8.3
Rh. neg. 35 24.9 Chi2 4.82 df 1
p < 0.028
Rh. pos. 131 141.1
Overall 166 166
events, recent studies showed no survival disadvantage for can-
cer patients suffering thrombosis (Riess et al., 2008; Agnelli et al.,
2009).
It is noteworthy that other cancer types do not have stringent
correlations to the AB0-antigen (Iodice et al., 2010), indicating it
to be a special observation in pancreatic cancer disease. But of all
above, the feasible research hypothesis is that the single base dele-
tion that generates the 0 blood group underlies the association
signal. Additional mapping and laboratory work is mandatory to
Table 3 | Calculations of AB0/Rhesus independence.
Blood group antigen Rhesus antigen All
Negative Positive
0
obs. pts. 5 38 43
exp. pts. 9.1 33.9
A
obs. pts. 21 73 94
exp. pts. 19.8 74.2
B
obs. pts. 5 11 16
exp. pts. 3.4 12.6
AB
obs. pts. 4 9 13
exp. pts. 2.7 10.3
All
obs. pts. 35 131 166
exp. pts.
Rhesus/AB0-proportions are independent (Chi2 4.13, df 3, p = 0.248).
determine which variants account for the observed correlation
(Amundadottir et al., 2009).
The discovery of additional genetic risk factors for this highly
lethal cancer type may contribute to novel risk stratifications
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and advances in prevention, early detection and therapeutic
approaches to pancreatic cancer.
Based on these representative data, we plan a genome map-
ping project of available data from our adjuvant studies (CONKO
001/005/006), which is under recent approval of the German
Society of Cancer.
CONCLUSIONS
The incidence of pancreatic cancer in Germany is signifi-
cantly associated with the AB0-blood group system. More
patients with blood group A suffer from pancreatic cancer (p <
0.001) whereas blood group 0 was less frequently observed
in patients with pancreatic cancer (p < 0.001). Genetic vari-
ations in the AB0 locus of 9q34 may influence the pan-
creatic carcinogenesis and increase the risk for patients with
blood group A and tapering the risk for patients with blood
group 0.
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